XML 26 R15.htm IDEA: XBRL DOCUMENT v3.25.3
SEGMENT INFORMATION
9 Months Ended
Sep. 30, 2025
SEGMENT INFORMATION  
SEGMENT INFORMATION

9.            SEGMENT INFORMATION

The Company operates as a single operating segment. The Company’s Chief Executive Officer, who serves as the Chief Operating Decision Maker (“CODM”), is responsible for allocating resources and assessing performance. The CODM reviews the Company’s operating results on an aggregate basis to make decisions about resource allocation, evaluate financial performance, and manage the overall business. Accordingly, the Company’s operations are managed as one reportable segment focused on the development and commercialization of its therapeutic candidates.

The following table represents consolidated net loss summarized by the significant segment expenses regularly reviewed by the CODM for the three and nine months ended September 30, 2025 and 2024:

Three months ended September 30, 

Nine months ended September 30, 

  

2025

  

2024

  

2025

  

2024

Total revenues

$

$

2,261,642

$

$

11,139,956

Research and development:

Compensation and benefits

9,586,659

4,461,233

27,176,680

13,314,847

Duchenne muscular dystrophy program (Deramiocel)

7,310,101

5,430,428

24,854,222

16,674,567

Exosomes platform research

1,474,937

842,952

4,160,004

2,518,052

Other R&D segment expenses (1)

1,987,401

1,073,254

5,131,018

2,906,183

Total research and development

20,359,098

11,807,867

61,321,924

35,413,649

General and administrative:

Compensation and benefits

3,314,529

2,323,384

11,672,488

7,516,797

Other G&A segment expenses (2)

2,610,413

1,140,271

5,991,710

3,076,511

Total general and administrative

5,924,942

3,463,655

17,664,198

10,593,308

Operating loss

(26,284,040)

(13,009,880)

(78,986,122)

(34,867,001)

Total non-operating income, net

1,713,393

453,152

4,113,090

1,516,418

Net loss

$

(24,570,647)

$

(12,556,728)

$

(74,873,032)

$

(33,350,583)

(1)Other R&D segment expenses primarily include other pipeline development costs, depreciation, amortization, and other facility costs.
(2)Other G&A segment expenses primarily include accounting, legal and other professional fees, consulting expenses, business insurance, employee travel, and other facility and information technology costs.